5 November 2025 - argenx today announced that Health Canada has issued a Notice of Compliance authorising Vvyvart SC (efgartigimod alfa injection) as a monotherapy for the treatment of adult patients with active chronic inflammatory demyelinating polyneuropathy.

Vyvgart SC is authorised for chronic inflammatory demyelinating polyneuropathy. as a once weekly 20-30 second subcutaneous injection in a pre-filled syringe, offering patients the flexibility to self-administer or receive treatment from a caregiver or health care professional—at home, while 'on the go,' or in a clinical setting. With this milestone, Vvygart SC becomes the first innovative treatment for chronic inflammatory demyelinating polyneuropathy. in more than 30 years, and the first-and-only neonatal Fc receptor blocker authorised in Canada for chronic inflammatory demyelinating polyneuropathy.

Read argenx press release